Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

This study tests a combination of Vyxeos (a dual chemotherapy drug) and gilteritinib (a targeted drug for FLT3-mutated leukemia) in people with acute myeloid leukemia (AML) that has come back or stopped responding to prior treatment. **You may be eligible if...** - You have AML (not the M3/promyelocytic subtype) with a FLT3-ITD or FLT3-TKD mutation confirmed at the time of relapse - Your cancer has relapsed or is refractory (not responding) to at least one prior AML treatment - Your physical health score (ECOG) is 2 or below - Your heart function (ejection fraction) is at least 50% - Your prior exposure to anthracycline chemotherapy (a class of drugs) is within safe limits - Your organ function is adequate **You may NOT be eligible if...** - You do not have a confirmed FLT3 mutation - You have AML subtype M3 (acute promyelocytic leukemia) - Your heart function is below the required threshold - You have active uncontrolled infections or other significant health problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.